Enable JavaScript to visit this website.

Oncology/Hematology Research Awards Program Apply Page

How to Apply

Two stage application process:

Stage 1: Study proposal (letter of intent) application: submit by email to [email protected]

Stage 2: Study protocol application will be invited from those applicants nominated by the External Review Committee

Required Documents

Complete submissions for Stage 1 must be accompanied by the following documents:
  • Study proposal (letter of intent)
    • Institutional format acceptable
    • Study proposal should at least include these components:
      • Title, PI, institution
      • Background and Rationale
      • Study Design
      • Study Objectives
      • Study Endpoint
      • Statistical Methods
      • Reference
  • Study budget
    • A high level budget including overhead, which is limited to 28%.
  • Study timelines
  • Enrollment period: expected within 12 months from study start
    • All study start up and initiation activities must begin by Q4, 2018
    • Primary results reported: expected within 18-24 months from study start
  • Curriculum vitae
    • Principle Investigator or Study Chair
  • If a proposal involves a novel non-Pfizer compound, a commitment letter from another company is required.

Note: Due to disease incidence/prevalence in certain patient populations, involving multiple institutions for a study may be appropriate to ensure timely enrollment.

Application Timelines

  • Stage 1 Application deadline: April 27, 2018 (by 11:59pm EST in the United States), NO EXCEPTIONS
  • Invitation announcement on selected investigators to submit full protocols for final decision: May, 2018
  • Final award recipients announcement: September, 2018
  • Study start up activities expected to start by: Q4, 2018
  • Award research expected to conclude by: December 2020

Note: Contracts not executed by Q4, 2018; initial data not reported by December 2020, - may risk loss of funding


See the Frequently Asked Questions (FAQ) for help.

You may also e-mail questions to [email protected]